ArticleMedicine2026
Prognostic value of the lactate-albumin ratio and development of a nomogram-based prediction model in patients with acute myocardial infarction-associated cardiogenic shock.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cardiogenic shock (CS) is a serious complication of acute myocardial infarction (AMI), associated with in-hospital mortality rates of more than 40%. There is a lack of accuracy and clinical applicability in the existing risk scores, emphasizing the need for improved prognostic models using novel biomarkers. This study aimed to evaluate the prognostic role of the lactate-to-albumin ratio (LAR) in AMI-CS patients and to construct a nomogram-based model incorporating LAR with conventional clinical indicators. This prospective study enrolled 129 AMI-CS patients admitted to the cardiac care unit of Renmin Hospital (November 2022-December 2024). Patients were divided into survivor (n = 106) and in-hospital mortality (n = 23) groups. Clinical and laboratory data were compared using univariate analysis. Variables with prognostic potential were initially screened using Least Absolute Shrinkage and Selection Operator regression before entering multivariable logistic analysis. A nomogram was constructed using independent predictors and evaluated using receiver operating characteristic-area under the curve (AUC), calibration analysis, Hosmer-Lemeshow testing, and decision curve analysis. LAR, cold and clammy skin, aspartate aminotransferase, C-reactive protein, and left ventricular ejection fraction < 40% emerged as independent predictors of in-hospital mortality. The median (interquartile range) for LAR was significantly higher in the in-hospital mortality group versus the survival group (2.82 [0.93-4.2] vs 0.59 [0.42-1.54]), P = .002. The best cutoff value for LAR was 1.997, with 65% sensitivity and 82% specificity. LAR had an AUC of 0.767, outperforming blood lactate (0.749), and showed strong prognostic value (odds ratio: 1.495, 95% confidence interval: 1.174-1.904, P = .001). The nomogram-based model achieved an AUC of 0.928, outperforming CardShock (0.782), Acute Physiology and Chronic Health Evaluation II (0.727), and blood lactate (0.749). The model demonstrated excellent calibration (mean absolute error: 0.04), and goodness-of-fit was confirmed (Hosmer-Lemeshow P = .648). Decision curve analysis indicated superior clinical usefulness. LAR is a meaningful indicator for early mortality risk in AMI-CS. The proposed nomogram may support faster decision-making and bedside risk evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.